Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US16323863Application Date: 2017-08-09
-
Publication No.: US10696651B2Publication Date: 2020-06-30
- Inventor: Jun Fujimoto , Xin Liu , Osamu Kurasawa , Terufumi Takagi , Douglas Robert Cary , Hiroshi Banno , Yasutomi Asano , Takuto Kojima
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka
- Agency: Wenderoth, Lind & Ponack, L.L.P.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@34470eb7 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6cb2fa1a
- International Application: PCT/JP2017/028928 WO 20170809
- International Announcement: WO2018/030466 WO 20180215
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D403/12 ; C07D401/14 ; C07D213/75 ; C07D405/12 ; C07D239/42 ; C07D241/12 ; C07D471/04 ; C07D498/04 ; C07D213/65 ; A61P35/00 ; C07D241/20 ; C07D213/73 ; A61K31/53 ; A61K31/505 ; A61K31/4406 ; A61K31/444 ; A61K31/4965 ; C07D213/68 ; C07D213/42 ; A61K31/506 ; A61K31/497 ; A61K31/4375 ; C07D239/20 ; A61P43/00 ; A61K31/5383 ; A61K31/437 ; A61K31/44 ; C07D253/06 ; C07D231/12 ; C07D239/30 ; C07D239/34 ; C07D239/48 ; C07D253/07 ; C07D409/12 ; C07D487/04
Abstract:
Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
Public/Granted literature
- US20190169166A1 HETEROCYCLIC COMPOUND Public/Granted day:2019-06-06
Information query
